Androgen Receptor Coregulators and Their Role in Prostate Cancer

  • Latif A. Wafa
  • Robert Snoek
  • Paul S. Rennie


The limiting factor in the survival of a patient with prostate cancer is the rate of progression to the noncurable androgen-independent (AI) stage of disease. The androgen receptor (AR) is a critical regulator of prostate cancer development and is involved in AI progression. Coregulators are proteins that interact directly with AR to enhance (coactivators) or reduce (corepressors) its transcriptional activity. Currently, over 165 AR coregulators have been discovered. In this chapter, we focus on a subset of the most well-characterized AR coregulators that are associated with prostate cancer. The first part of our review discusses the mechanisms by which classical type I and nonclassical type II AR coactivators/corepressors regulate AR transcriptional activity. The second section focuses on the role of coregulators in prostate cancer, including their expression profile in prostate cancer patients, tumor cell growth effects, and potential as therapeutic targets. In view of their involvement in prostate cancer progression, it is anticipated that further study of AR coregulators will provide more treatment options for increasing survival of patients with AI prostate cancer.


Prostate Cancer Androgen Receptor Prostate Cancer Cell Androgen Deprivation Therapy Androgen Receptor Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aaltomaa S. et al. 2005. Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Res 25:4707–4712.PubMedGoogle Scholar
  2. Aarnisalo P. et al. 1998. CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci U S A 95:2122–2127.PubMedGoogle Scholar
  3. Albertsen P. C. et al. 2005. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101.PubMedGoogle Scholar
  4. Alen P. et al. 1999. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 19:6085–6097.PubMedGoogle Scholar
  5. Agoulnik I. U. et al. 2005. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65:7959–7967.PubMedGoogle Scholar
  6. Agoulnik I. U. et al. 2006. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66:10594–10602.PubMedGoogle Scholar
  7. Assikis V. J. et al. 2004. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10:6770–6778.PubMedGoogle Scholar
  8. Bakin R. E. et al. 2003. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981–1989.PubMedGoogle Scholar
  9. Beliakoff J. and Sun Z. 2006. Zimp7 and Zimp10, two novel PIAS-like proteins, function as androgen receptor coregulators. Nucl Recept Signal 4:e017.PubMedGoogle Scholar
  10. Black B. E. et al. 2004. Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. Mol Endocrinol 18:834–850.PubMedGoogle Scholar
  11. Blanco J. C. et al. 1998. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 12:1638–1651.PubMedGoogle Scholar
  12. Bohen S. P. et al. 1995. Hold ‘em and fold ‘em: chaperones and signal transduction. Science 268:1303–1304.PubMedGoogle Scholar
  13. Boonyaratanakornkit V. and Edwards D. P. 2007. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 25:139–153.PubMedGoogle Scholar
  14. Brady M. E. et al. 1999. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 274:17599–17604.PubMedGoogle Scholar
  15. Buchanan G. et al. 2007. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 67:10087–10096.PubMedGoogle Scholar
  16. Bukau B. and Horwich A. L. 1998. The Hsp70 and Hsp60 chaperone machines. Cell 92:351–366.PubMedGoogle Scholar
  17. Burd C. J. et al. 2006a. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 13:979–994.Google Scholar
  18. Burd C. J. et al. 2006b. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A 103:2190–2195.Google Scholar
  19. Callewaert L. et al. 2006. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 66:543–553.PubMedGoogle Scholar
  20. Caplan A. J. and Douglas M. G. 1991. Characterization of YDJ1: a yeast homologue of the bacterial dnaJ protein. J Cell Biol 114:609–621.PubMedGoogle Scholar
  21. Caplan A. J. et al. 1995. Hormone-dependent transactivation by the human androgen receptor is regulated by a dnaJ protein. J Biol Chem 270:5251–5257.PubMedGoogle Scholar
  22. Casimiro M. et al. 2007. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res 67:4364–4372.PubMedGoogle Scholar
  23. Chakravarti D. et al. 1996. Role of CBP/P300 in nuclear receptor signalling. Nature 383:99–103.PubMedGoogle Scholar
  24. Chang H. C. et al. 2005. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line. J Formos Med Assoc 104:652–658.PubMedGoogle Scholar
  25. Chang Y. M. et al. 2007. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 9:90–100.PubMedGoogle Scholar
  26. Chen H. et al. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580.PubMedGoogle Scholar
  27. Cheng H. et al. 2006. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613–10620.PubMedGoogle Scholar
  28. Cheng S. et al. 2002. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 16:1492–1501.PubMedGoogle Scholar
  29. Chesire D. R. et al. 2002. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21:2679–2694.PubMedGoogle Scholar
  30. Chiba H. et al. 1994. Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucleic Acids Res 22:1815–1820.PubMedGoogle Scholar
  31. Chmelar R. et al. 2007. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120:719–733.PubMedGoogle Scholar
  32. Choudhry M. A. et al. 2006. The role of the general transcription factor IIF in androgen receptor-dependent transcription. Mol Endocrinol 20:2052–2061.PubMedGoogle Scholar
  33. Chung A. C. et al. 2007. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 67:5965–5975.PubMedGoogle Scholar
  34. Cinar B. et al. 2007. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem 282:29584–29593.PubMedGoogle Scholar
  35. Comuzzi B. et al. 2004. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204:159–166.PubMedGoogle Scholar
  36. Cronauer M. V. et al. 2004. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23:3541–3549.PubMedGoogle Scholar
  37. Culig Z. and Bartsch G. 2006. Androgen axis in prostate cancer. J Cell Biochem 99:373–381.PubMedGoogle Scholar
  38. Culig Z. et al. 2003. Androgen receptors in prostate cancer. J Urol 170:1363–1369.PubMedGoogle Scholar
  39. Culig Z. et al. 2005. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 12:229–244.PubMedGoogle Scholar
  40. Dasso M. 2001. Running on Ran: nuclear transport and the mitotic spindle. Cell 104:321–324.PubMedGoogle Scholar
  41. Davies T. H. et al. 2002. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem 277:4597–4600.PubMedGoogle Scholar
  42. Debes J. D. et al. 2002. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632–5636.PubMedGoogle Scholar
  43. Debes J. D. et al. 2003. p300 in prostate cancer proliferation and progression. Cancer Res 63:7638–7640.PubMedGoogle Scholar
  44. Dedhar S. et al. 1994. Inhibition of nuclear hormone receptor activity by calreticulin. Nature 367:480–483.PubMedGoogle Scholar
  45. Dehm S. M. and Tindall D. J. 2007. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 21:2855–2863.PubMedGoogle Scholar
  46. Desai S. J. et al. 2006. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res 66:10449–10459.PubMedGoogle Scholar
  47. Ding X. F. et al. 1998. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12:302–313.PubMedGoogle Scholar
  48. Dittmar K. D. et al. 1998. The role of DnaJ-like proteins in glucocorticoid receptor.hsp90 heterocomplex assembly by the reconstituted hsp90.p60.hsp70 foldosome complex. J Biol Chem 273:7358–7366.PubMedGoogle Scholar
  49. Dong X. et al. 2007. Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol Cell Biol 27:4863–4875.PubMedGoogle Scholar
  50. Dotzlaw H. et al. 2002. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16:661–673.PubMedGoogle Scholar
  51. Dressel U. et al. 1999. Alien, a highly conserved protein with characteristics of a corepressor for members of the nuclear hormone receptor superfamily. Mol Cell Biol 19:3383–3394.PubMedGoogle Scholar
  52. Drobnjak M. et al. 2000. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 6:1891–1895.PubMedGoogle Scholar
  53. Dubbink H. J. et al. 2004. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol 18:2132–2150.PubMedGoogle Scholar
  54. Edwards J. and Bartlett J. M. 2005a. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 95:1320–1326.Google Scholar
  55. Edwards J. and Bartlett J. M. 2005b. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95:1327–1335.Google Scholar
  56. Estebanez-Perpina E. et al. 2007. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A 104:16074–16079PubMedGoogle Scholar
  57. Fan C. Y. et al. 2005. The type I Hsp40 zinc finger-like region is required for Hsp70 to capture non-native polypeptides from Ydj1. J Biol Chem 280:695–702.PubMedGoogle Scholar
  58. Fang Y. et al. 1996. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 271:28697–28702.PubMedGoogle Scholar
  59. Fletterick R. J. 2005. Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer. BJU Int 96(Suppl 2):2–9.PubMedGoogle Scholar
  60. Ford O. H., 3rd et al. 2003. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170:1817–1821.PubMedGoogle Scholar
  61. Freeman B. C. et al. 2000. The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies. Genes Dev 14:422–434.PubMedGoogle Scholar
  62. Freeman M. R. et al. 2005. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 16:273–279.PubMedGoogle Scholar
  63. Froesch B. A. et al. 1998. BAG-1L protein enhances androgen receptor function. J Biol Chem 273:11660–11666.PubMedGoogle Scholar
  64. Fronsdal K. et al. 1998. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 273:31853–31859.PubMedGoogle Scholar
  65. Fu M. et al. 2000. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853–20860.PubMedGoogle Scholar
  66. Fu M. et al. 2003. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563–8575.PubMedGoogle Scholar
  67. Fujimoto N. et al. 2007. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest 25:32–37.PubMedGoogle Scholar
  68. Gaddipati J. P. et al. 1994. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864.PubMedGoogle Scholar
  69. Gao W. and Dalton J. T. 2007. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 12:241–248.PubMedGoogle Scholar
  70. Gao N. et al. 2003. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 17:1484–1507.PubMedGoogle Scholar
  71. Gaughan L. et al. 2002. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 277:25904–25913.PubMedGoogle Scholar
  72. Gehin M. et al. 2002. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 22:5923–5937.PubMedGoogle Scholar
  73. Ghosh P. M. et al. 2003. Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 4:487–496.PubMedGoogle Scholar
  74. Gioeli D. 2005. Signal transduction in prostate cancer progression. Clin Sci (Lond) 108:293–308.Google Scholar
  75. Gnanapragasam V. J. et al. 2001. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928–1936.PubMedGoogle Scholar
  76. Gobinet J. et al. 2001. Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP. Biochemistry 40:15369–15377.PubMedGoogle Scholar
  77. Gobinet J. et al. 2005. SHP represses transcriptional activity via recruitment of histone deacetylases. Biochemistry 44:6312–6320.PubMedGoogle Scholar
  78. Gong J. et al. 2006. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 25:2011–2021.PubMedGoogle Scholar
  79. Graff J. R. et al. 2000. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275:24500–24505.PubMedGoogle Scholar
  80. Gregory C. W. et al. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315–4319.PubMedGoogle Scholar
  81. Gregory C. W. et al. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119–7130.PubMedGoogle Scholar
  82. Gregory C. W. et al. 2005. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11:1704–1712.PubMedGoogle Scholar
  83. Guo Z. et al. 2006. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10:309–319.PubMedGoogle Scholar
  84. Halkidou K. et al. 2003. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22:2466–2477.PubMedGoogle Scholar
  85. Halvorsen O. J. et al. 2003. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9:1474–1479.PubMedGoogle Scholar
  86. Harashima K. et al. 2005. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int J Radiat Biol 81:63–76.PubMedGoogle Scholar
  87. He B. et al. 1999. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219–37225.PubMedGoogle Scholar
  88. He B. et al. 2001. Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276:42293–42301.PubMedGoogle Scholar
  89. He B. et al. 2002. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 277:10226–10235.PubMedGoogle Scholar
  90. He B. et al. 2006. Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. J Biol Chem 281:6648–6663.PubMedGoogle Scholar
  91. Heemers H. V. and Tindall D. J. 2005. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Current Cancer Therapy Reviews 1:175–186.Google Scholar
  92. Heemers H. V. and Tindall D. J. 2007. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778–808.PubMedGoogle Scholar
  93. Heery D. M. et al. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736.PubMedGoogle Scholar
  94. Heinlein C. A. and Chang C. 2002. Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175–200.PubMedGoogle Scholar
  95. Heinlein C. A. and Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276–308.PubMedGoogle Scholar
  96. Hermanson O. et al. 2002. N-CoR controls differentiation of neural stem cells into astrocytes. Nature 419:934–939.PubMedGoogle Scholar
  97. Hobisch A. et al. 1995. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068–3072.PubMedGoogle Scholar
  98. Holter E. et al. 2002. Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Mol Endocrinol 16:515–528.PubMedGoogle Scholar
  99. Hong H. et al. 2004. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101:83–89.PubMedGoogle Scholar
  100. Hsiao P. W. and Chang C. 1999. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem 274:22373–22379.PubMedGoogle Scholar
  101. Hsiao P. W. et al. 1999. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 274:20229–20234.PubMedGoogle Scholar
  102. Hu Y. C. et al. 2004. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 279:33438–33446.PubMedGoogle Scholar
  103. Huang Z. Q. et al. 2003. A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and mediator for transcription. Embo J 22:2146–2155.PubMedGoogle Scholar
  104. Ikonen T. et al. 1997. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 272:29821–29828.PubMedGoogle Scholar
  105. Jemal A. et al. 2004. Cancer statistics, 2004. CA Cancer J Clin 54:8–29.PubMedGoogle Scholar
  106. Kahl P. et al. 2006. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66:11341–11347.PubMedGoogle Scholar
  107. Kaltz-Wittmer C. et al. 2000. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80:1455–1464.PubMedGoogle Scholar
  108. Kampa M. et al. 2002. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. Faseb J 16:1429–1431.PubMedGoogle Scholar
  109. Karam J. A. et al. 2007. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67:614–622.PubMedGoogle Scholar
  110. Kent E. C. and Hussain M. H. 2003. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat. Urology 62(Suppl 1):134–140.PubMedGoogle Scholar
  111. Kim J. et al. 2005. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol 34:107–118.PubMedGoogle Scholar
  112. Knudsen K. E. et al. 1999a. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59:2297–2301.Google Scholar
  113. Knudsen K. E. et al. 1999b. The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene 18:5239–5245.Google Scholar
  114. Kornberg R. D. 2007. The molecular basis of eukaryotic transcription. Proc Natl Acad Sci U S A 104:12955–12961.PubMedGoogle Scholar
  115. Kosano H. et al. 1998. The assembly of progesterone receptor-hsp90 complexes using purified proteins. J Biol Chem 273:32973–32979.PubMedGoogle Scholar
  116. Krajewska M. et al. 2006. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate 66:801–810.PubMedGoogle Scholar
  117. Kraus S. et al. 2006. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 66:11047–11054.PubMedGoogle Scholar
  118. Krongrad A. et al. 1991. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 76:79–88.PubMedGoogle Scholar
  119. Kumar R. et al. 2005. The clinical relevance of steroid hormone receptor corepressors. Clin Cancer Res 11:2822–2831.PubMedGoogle Scholar
  120. LaFevre-Bernt M. A. and Ellerby L. M. 2003. Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem 278:34918–34924.PubMedGoogle Scholar
  121. Lambert J. R. and Nordeen S. K. 2003. CBP recruitment and histone acetylation in differential gene induction by glucocorticoids and progestins. Mol Endocrinol 17:1085–1094.PubMedGoogle Scholar
  122. Lange C. A. et al. 2007. Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu Rev Physiol 69:171–199.PubMedGoogle Scholar
  123. Lee D. K. and Chang C. 2003. Molecular communication between androgen receptor and general transcription machinery. J Steroid Biochem Mol Biol 84:41–49.PubMedGoogle Scholar
  124. Lee D. K. et al. 2000. From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. J Biol Chem 275:9308–9313.PubMedGoogle Scholar
  125. Lee D. K. et al. 2003. The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor. Biochem Biophys Res Commun 302:162–169.PubMedGoogle Scholar
  126. Li J. et al. 2006. A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol 20:776–785.PubMedGoogle Scholar
  127. Li J. et al. 2007. Structural and functional analysis of androgen receptor in chromatin. Mol Endocrinol [Epub ahead of print, doi:10.1210/me.2006–0221]Google Scholar
  128. Li L. et al. 2003. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23:9389–9404.PubMedGoogle Scholar
  129. Li P. et al. 2001. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 276:20444–20450.PubMedGoogle Scholar
  130. Liao G. et al. 2003. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 278:5052–5061.PubMedGoogle Scholar
  131. Lin H. K. et al. 2001. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 98:7200–7205.PubMedGoogle Scholar
  132. Lin H. K. et al. 2003. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278:50902–50907.PubMedGoogle Scholar
  133. Lin H. K. et al. 2004. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18:2409–2423.PubMedGoogle Scholar
  134. Linja M. J. et al. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550–3555.PubMedGoogle Scholar
  135. Link K. A. et al. 2005. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol 25:2200–2215.PubMedGoogle Scholar
  136. Lonard D. M. et al. 2007. Nuclear receptor coregulators and human disease. Endocr Rev 28:575–587.PubMedGoogle Scholar
  137. Loy C. J. et al. 2003. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci U S A 100:4562–4567.PubMedGoogle Scholar
  138. Lu M. L. et al. 2001. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276:13442–13451.PubMedGoogle Scholar
  139. Lyng F. M. et al. 2000. Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations. Biol Reprod 63:736–747.PubMedGoogle Scholar
  140. Ma A. H. et al. 2006. Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells. Cancer Res 66:8439–8447.PubMedGoogle Scholar
  141. Maki H. E. et al. 2006. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 66:1391–1398.PubMedGoogle Scholar
  142. Maki H. E. et al. 2007. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. J Pathol 212:395–401.PubMedGoogle Scholar
  143. Marcelli M. et al. 2000. Androgen receptor mutations in prostate cancer. Cancer Res 60:944–949.PubMedGoogle Scholar
  144. Marivoet S. et al. 1992. Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Mol Cell Endocrinol 88:165–174.PubMedGoogle Scholar
  145. Mark M. et al. 2004. Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction. Proc Natl Acad Sci U S A 101:4453–4458.PubMedGoogle Scholar
  146. Marshall T. W. et al. 2003. Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem 278:30605–30613.PubMedGoogle Scholar
  147. Martel C. L. et al. 2003. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 29:171–187.PubMedGoogle Scholar
  148. Mattie M. D. et al. 2006. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24.PubMedGoogle Scholar
  149. Mayeur G. L. et al. 2005. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J Biol Chem 280:10827–10833.PubMedGoogle Scholar
  150. McEwan I. J. and Gustafsson J. 1997. Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. Proc Natl Acad Sci U S A 94:8485–8490.PubMedGoogle Scholar
  151. McKenna N. J. et al. 1999. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321–344.PubMedGoogle Scholar
  152. McMenamin M. E. et al. 1999. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291–4296.PubMedGoogle Scholar
  153. Migliaccio A. et al. 2007. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene 26:6619–6629.PubMedGoogle Scholar
  154. Mills I. G. et al. 2005. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 170:191–200.PubMedGoogle Scholar
  155. Miyamoto H. et al. 1998. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A 95:7379–7384.PubMedGoogle Scholar
  156. Miyamoto H. et al. 2004. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 91:3–12.PubMedGoogle Scholar
  157. Moehren U. et al. 2007. Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol Endocrinol 21:1039–1048.PubMedGoogle Scholar
  158. Mohler J. L. et al. 2004. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440–448.PubMedGoogle Scholar
  159. Moilanen A. M. et al. 1998. Activation of androgen receptor function by a novel nuclear protein kinase. Mol Biol Cell 9:2527–2543.PubMedGoogle Scholar
  160. Mostaghel E. A. et al. 2007a. The basic biochemistry and molecular events of hormone therapy. Curr Urol Rep 8:224–232.Google Scholar
  161. Mostaghel E. A. et al. 2007b. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033–5041.Google Scholar
  162. Mulholland D. J. et al. 2002. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277:17933–17943.Google Scholar
  163. Nair S. S. et al. 2007. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 21:613–624.PubMedGoogle Scholar
  164. Neckers L. and Ivy S. P. 2003. Heat shock protein 90. Curr Opin Oncol 15:419–424.PubMedGoogle Scholar
  165. Needham M. et al. 2000. Differential interaction of steroid hormone receptors with LXXLL motifs in SRC-1a depends on residues flanking the motif. J Steroid Biochem Mol Biol 72:35–46.PubMedGoogle Scholar
  166. Newmark J. R. et al. 1992. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 89:6319–6323.PubMedGoogle Scholar
  167. Nishimura K. et al. 2003. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 63:4888–4894.PubMedGoogle Scholar
  168. Nwachukwu J. C. et al. 2007. Transcriptional regulation of the androgen receptor cofactor androgen receptor trapped clone-27. Mol Endocrinol 21:2864–2876.PubMedGoogle Scholar
  169. Ogryzko V. V. et al. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953–959.PubMedGoogle Scholar
  170. Onate S. A. et al. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357.PubMedGoogle Scholar
  171. Owens-Grillo J. K. et al. 1996. A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. J Biol Chem 271:13468–13475.PubMedGoogle Scholar
  172. Ozanne D. M. et al. 2000. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol 14:1618–1626.PubMedGoogle Scholar
  173. Ozers M. S. et al. 2007. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46:683–695.PubMedGoogle Scholar
  174. Paez J. and Sellers W. R. 2003. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 115:145–167.PubMedGoogle Scholar
  175. Papakonstanti E. A. et al. 2003. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 17:870–881.PubMedGoogle Scholar
  176. Pedram A. et al. 2007. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 282:22278–22288.PubMedGoogle Scholar
  177. Petre-Draviam C. E. et al. 2005. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 24:431–444.PubMedGoogle Scholar
  178. Petrylak D. P. 2005. Future directions in the treatment of androgen-independent prostate cancer. Urology 65:8–12.PubMedGoogle Scholar
  179. Porkka K. P. et al. 2007. MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135.PubMedGoogle Scholar
  180. Pratt W. B. and Toft D. O. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306–360.PubMedGoogle Scholar
  181. Prescott J. and Coetzee G. A. 2006. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 231:12–19.PubMedGoogle Scholar
  182. Rao D. S. et al. 2002a. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 110:351–360.Google Scholar
  183. Rao M. A. et al. 2002b. RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. J Biol Chem 277:48020–48027.Google Scholar
  184. Rassow J. et al. 1995. Partner proteins determine multiple functions of Hsp70. Trends Cell Biol 5:207–212.PubMedGoogle Scholar
  185. Ray M. R. et al. 2006. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 118:1108–1119.PubMedGoogle Scholar
  186. Ratajczak T. 2001. Protein coregulators that mediate estrogen receptor function. Reprod Fertil Dev 13:221–229.PubMedGoogle Scholar
  187. Rennie P. S. and Nelson C. C. 1998. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 17:401–409.PubMedGoogle Scholar
  188. Reutens A. T. et al. 2001. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 15:797–811.PubMedGoogle Scholar
  189. Rhodes D. 1997. Chromatin structure. The nucleosome core all wrapped up. Nature 389:231–233.Google Scholar
  190. Rocchi P. et al. 2004. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64:6595–6602.PubMedGoogle Scholar
  191. Rochette-Egly C. 2003. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal 15:355–366.PubMedGoogle Scholar
  192. Roeder R. G. 1996. The role of general initiation factors in transcription by RNA polymerase II. Trends Biochem Sci 21:327–335.PubMedGoogle Scholar
  193. Rosenfeld M. G. and Glass C. K. 2001. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865–36868.PubMedGoogle Scholar
  194. Rosenfeld M. G. et al. 2006. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20:1405–1428.PubMedGoogle Scholar
  195. Ross J. S. 2007. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test. Adv Anat Pathol 14:353–357.PubMedGoogle Scholar
  196. Sadar M. D. et al. 1999. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6:487–502.PubMedGoogle Scholar
  197. Shah R. B. et al. 2004. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209–9216.PubMedGoogle Scholar
  198. Sharma M. et al. 2000. Androgen receptor interacts with a novel MYST protein, HBO1. J Biol Chem 275:35200–35208.PubMedGoogle Scholar
  199. Shatkina L. et al. 2003. The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol Cell Biol 23:7189–7197.PubMedGoogle Scholar
  200. Shenk J. L. et al. 2001. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 276:38472–38479.PubMedGoogle Scholar
  201. Shi X. B. et al. 2002. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62:1496–1502.PubMedGoogle Scholar
  202. Shi X. B. et al. 2004. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value. BJU Int 94:996–1002.PubMedGoogle Scholar
  203. Singh P. et al. 2006. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13:653–666.PubMedGoogle Scholar
  204. Smith C. L. and O'Malley B. W. 2004. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45–71.PubMedGoogle Scholar
  205. Smith D. F. and Toft D. O. 1993. Steroid receptors and their associated proteins. Mol Endocrinol 7:4–11.PubMedGoogle Scholar
  206. Spencer T. E. et al. 1997. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194–198.PubMedGoogle Scholar
  207. Stossel T. P. et al. 1985. Nonmuscle actin-binding proteins. Annu Rev Cell Biol 1:353–402.PubMedGoogle Scholar
  208. Sun J. et al. 2007. Cofactor of BRCA1 modulates androgen-dependent transcription and alternative splicing. J Steroid Biochem Mol Biol 107:131–139.PubMedGoogle Scholar
  209. Takeshita A. et al. 1996. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology 137:3594–3597.PubMedGoogle Scholar
  210. Taneja S. S. et al. 2004. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 279:13944–13952.PubMedGoogle Scholar
  211. Taneja S. S. et al. 2005. Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem 280:40916–40924.PubMedGoogle Scholar
  212. Tannock I. F. et al. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512.PubMedGoogle Scholar
  213. Taplin M. E. and Balk S. P. 2004. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483–490.PubMedGoogle Scholar
  214. Taplin M. E. et al. 2003. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673–2678.PubMedGoogle Scholar
  215. Thomas M. et al. 2006. Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum Mol Genet 15:1876–1883.PubMedGoogle Scholar
  216. Tilley W. D. et al. 1994. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 54:4096–4102.PubMedGoogle Scholar
  217. Tillman J. E. et al. 2007. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 67:4630–4637.PubMedGoogle Scholar
  218. Ting H. J. et al. 2002. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci U S A 99:661–666.PubMedGoogle Scholar
  219. Truica C. I. et al. 2000. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709–4713.PubMedGoogle Scholar
  220. Ueda T. et al. 2002. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087–38094.PubMedGoogle Scholar
  221. Unni E. et al. 2004. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64:7156–7168.PubMedGoogle Scholar
  222. Vadlamudi R. K. and Kumar R. 2007. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 5:e004.PubMedGoogle Scholar
  223. Veldscholte J. et al. 1992. Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 31:7422–7430.PubMedGoogle Scholar
  224. Visakorpi T. et al. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406.PubMedGoogle Scholar
  225. Volinia S. et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103:2257–2261.PubMedGoogle Scholar
  226. Wafa L. A. et al. 2003. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 375:373–383.PubMedGoogle Scholar
  227. Wafa L. A. et al. 2007. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 38:161–170.PubMedGoogle Scholar
  228. Wang L. et al. 2004. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 279:32444–32452.PubMedGoogle Scholar
  229. Wang L. et al. 2005. Androgen receptor corepressors: an overview. Prostate 63:117–130.PubMedGoogle Scholar
  230. Wang Q. et al. 2001a. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 276:7493–7499.Google Scholar
  231. Wang S. et al. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209–221.PubMedGoogle Scholar
  232. Wang X. et al. 2001b. Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. J Biol Chem 276:40417–40423.Google Scholar
  233. Weigel N. L. and Moore N. L. 2007. Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl Recept Signal 5:e005.PubMedGoogle Scholar
  234. Wen Y. et al. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841–6845.PubMedGoogle Scholar
  235. Xin L. et al. 2006. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A 103:7789–7794.PubMedGoogle Scholar
  236. Xu J. et al. 1998. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922–1925.PubMedGoogle Scholar
  237. Xu L. et al. 1999. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 9:140–147.PubMedGoogle Scholar
  238. Yao T. P. et al. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361–372.PubMedGoogle Scholar
  239. Yan J. et al. 2006. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 66:11039–11046.PubMedGoogle Scholar
  240. Yeh S. and Chang C. 1996. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A 93:5517–5521.PubMedGoogle Scholar
  241. Yeh S. et al. 1998. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 248:361–367.PubMedGoogle Scholar
  242. Yeh S. et al. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96:5458–5463.PubMedGoogle Scholar
  243. Yeh S. et al. 2000. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci U S A 97:11256–11261.PubMedGoogle Scholar
  244. Yong W. et al. 2007. Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J Biol Chem 282:5026–5036.PubMedGoogle Scholar
  245. Yoon H. G. and Wong J. 2006. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 20:1048–1060.PubMedGoogle Scholar
  246. Zhang F. P. et al. 2007. An adenosine triphosphatase of the sucrose nonfermenting 2 family, androgen receptor-interacting protein 4, is essential for mouse embryonic development and cell proliferation. Mol Endocrinol 21:1430–1442.PubMedGoogle Scholar
  247. Zhou H. J. et al. 2005. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 65:7976–7983.PubMedGoogle Scholar
  248. Zhou J. et al. 2006. Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle. Cancer Res 66:8954–8958.PubMedGoogle Scholar
  249. Zhoul J. et al. 2005. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 65:9906–9913.PubMedGoogle Scholar
  250. Zou J. X. et al. 2006. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate 66:1474–1486.PubMedGoogle Scholar
  251. Zoubeidi A. et al. 2007. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67:10455–10465.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Urologic Sciences, Faculty of MedicineUniversity of British Columbia, Prostate Centre at Vancouver General HospitalCanada, V6H

Personalised recommendations